| 查看: 11630 | 回复: 22 | |||||||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||||||
[交流]
诺华上海研发中心招聘
|
|||||||
China Novartis Institutes for BioMedical Research Co., Ltd. (CNIBR) has some job vacancies as below. If you have interested in these jobs, please send your resume with no hesitation cause we'll provide you more chance to promote yourself in your field. (Sr.) Investigator, Medicinal Chemistry Investigator, Bioinformatics Investigator II/III, Hair Cell Investigator, Epigenetics of Cancer Drug Discovery Investigator, Developmental Biology Scientist I/II, Cellular Assays Investigator, Computer-Aided Drug Design Clinical Trial Head Head of Scientific Operations For more details, please click our career website: http://careers.novartis.com.cn/vacancies.html To apply this position, please send your resume to sarah.qi@novartis.com When you send your resume to sarah.qi@novartis.com, please notice you know this position information via 小木虫BBS 诺华（中国）生物医学研究有限公司是诺华全球研发组织――诺华生物医学研究所（NIBR）的第八个研究基地。我们位于中国上海市张江高科技园区，将成为诺华在亚洲的主要研究中心，以及除在欧美的研究中心外的最主要的研究中心。我们的研究和探索开发活动的重点是发现并开发创新疗法，用于治疗在亚洲远未达到医药需求的疾病。我们与从不同之处在于将专注现代药物的发现和开发方法的研究。最初阶段，研发工作将专注在引起中国地方性癌症的感染原因。我们还将开展临床试验，进行安全性研究，生物标志物和检测分析，表达谱、生物分析以及转化医学的研究。 随着公司业务的迅速扩展，我们热忱欢迎您的加入。同时我们将提供具有竞争力的薪酬福利待遇以及良好的培训发展机会。 NIBR Shanghai NIBR Shanghai is an integrated research center that is part of the Novartis global research and development network. The establishment of this strategic site is a commitment by Novartis to conduct cutting-edge pharmaceutical research in China. Research activities at NIBR Shanghai focus on addressing urgent medical needs in China, particularly infectious causes of cancer endemic to the region. The center also established programs in epigenetics, biomarker development, drug metabolism and preclinical safety to support NIBR local and global R&D projects.Research at NIBR Shanghai is currently focused on discovering new therapies for infectious causes of cancer, such as liver cancer caused by HBV or HCV hepatitis. As the diseases are highly prevalent in the region, some one-third of the 400 million people infected with the hepatitis B virus are in China, with estimates that 300,000 people die from liver cancer in the mainland each year. A Growing and Dynamic Organization China Novartis Institutes for BioMedical Research Co., Ltd. (CNIBR), the legal entity for NIBR Research Center in Shanghai was launched in November 2006 and the start-up Research facilities opened in April 2007. Today, NIBR Shanghai has grown to an organization of about 260 associates including nearly 200 scientists. The research teams are comprised of both returnee scientists from abroad (about 20% of total scientists), and graduates from top tier universities, medical centers, and research institutes in China. Currently the center operates in an office building and two lab facilities in the Zhangjiang Hi-Tech Park. In the same area, the new Novartis Shanghai Campus is under design and construction. The first phase of the project will be completed by the end of 2014. [ Last edited by saliand on 2013-8-7 at 15:17 ] Investigator II Job Purpose Manage projects (with a TA focus), interpret and present information and negotiate an optimal PK/PD strategy for early and late development in liaison with TA-PK Head and appropriate line functions. Responsible for the PK, PK/PD and M&S component of study protocols, reports and project summaries within agreed timeframes and which meet regulatory requirements. Take the lead on appropriate pharmacokinetic /biopharmaceutical studies. Major Accountabilities • Define PK, PK/PD, biopharmaceutical and M&S requirements in project (nonclinical and clinical) development plans and appropriate strategies for global registration. • Analyze, interpret and represent PK, PK/PD and M&S data generated during development and provide guidance. • Proactively manage links with other functions to ensure that pre-clinical and clinical PK/PD information are used optimally. • Directly or indirectly take the lead on appropriate pharmacokinetic/biopharmaceutical studies. • Prepare summary information for internal and external Advisory panels, Investigator meetings and Health Authorities as part of the regulatory approval process. This includes PK/PD components of IND applications in the US, CTX in other countries. • Represent the PK/PD discipline and ensure high quality interactions with various health authorities, external investigators, and various internal Novartis Disease Area experts • Coordinate with appropriate sub-team members and other LF experts and/ or prepare (when needed) summary documentation on drug metabolism and pharmacokinetics as required by ethics committees and HAs (IB, BB, CTA/IND, responses to HAs). • Prepare, compile and review appropriate sections of CTD dossiers /NDA documents. • Contribute to and support continuous improvement initiatives in global pharmacokinetics and partner functions Ideal Background Education: Ph.D. in Pharmaceutical Sciences, or related disciplines (or equivalent degree/knowledge/expertise) Languages: fluent English and Chinese (spoken and written) Experience: 3-4 years of experiences in drug development or a relevant environment [ Last edited by saliand on 2013-10-12 at 17:49 ] |
回复此楼» 猜你喜欢
博士读完未来一定会好吗
已经有6人回复
-
小论文投稿
已经有3人回复
-
Bioresource Technology期刊，第一次返修的时候被退回好几次了
已经有9人回复
-
心脉受损
已经有3人回复
-
到新单位后，换了新的研究方向，没有团队，持续积累2区以上论文，能申请到面上吗
已经有8人回复
-
申请2026年博士
已经有6人回复
-
请问哪里可以有青B申请的本子可以借鉴一下。
已经有5人回复
 |
22楼2013-09-19 22:37:46